Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 25/2/2021
SIETES contiene 93212 citas

 
 
 1 a 20 de 5184 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Yeoh YK, Zuo T, Lui GC-Y, Zhang F, Liu Q, Li AYL, Chung ACK, Cheung CP, Tso EYK, Fung KSC, Chan V, Ling L, Joynt G, Hui DS-C, Chow KM, Ng SSS, Li TC-M, Ng RWY, Yip TCF, Wong GL-H, Chan FKL, Wong CK, Chan PKS, Ng SC. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut 2020:30 de diciembre. [Ref.ID 103837]
3.Enlace a cita originalTiene citas relacionadas Cita con resumen
Aby ES, Rodin H, Debes JD. Proton pump inhibitors and mortality in individuals with COVID-19. The American Journal of Gastroenterology 2020;115:octubre. [Ref.ID 103830]
4. Cita con resumen
Weigand AJ, Bondi.MW, Thomas KR, Campbell NL, et al.. Association of anticholinergic medications and AD biomarkers with incidence of MCI among cognitively normal older adults. Neurology 2020;95:e2295-304. [Ref.ID 103815]
5.Tiene citas relacionadas Cita con resumen
Zhou J, Wang X, Lee S, Wu WKK, Cheung BMY, Zhang Q, Tse G. Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study. Gut 2020:diciembre. [Ref.ID 103806]
6.Enlace a cita originalTiene citas relacionadas Cita con resumen
Almario CV, Chey WD, Spiegel BMR. Increased risk of COVID-19 among users of proton-pump inhibitors. The American Journal of Gastroenterology 2020;115:octubre. [Ref.ID 103795]
7. Cita con resumen
Zhang X-Y, Wu H-B, Ling Y, Qian Z-P, Chen L. Analysis of the effect of proton pump inhibitors on the course of common COVID-19. medRxiv 2020:13 de junio. [Ref.ID 103794]
8. Cita con resumen
Jimenez L, Campos Codo A, de Souza Sampaio V, Oliveira AER, Kobo Ferreira LK, Gastao Davanzo G, et al.. The influence of pH on SARS-CoV-2 infection and COVID-19 severity. medRxiv 2020:. [Ref.ID 103792]
9. Cita con resumen
Vila-Corcoles A, Satue-Gracia E, Ochoa-Gondar O, Torrente-Fraga C, Gomez-Bertomeu F, Vila-Rovira A, Hospital-Guardiola I, de Diego-Cabanes C, Bejarano-Romero F, Rovira-Veciana D, Basora-Gallisa J. Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: A population-based cohort study in Southern Catalonia, Spain. The Journal of Clinical Hypertension 2020;22:agosto. [Ref.ID 103791]
10.Enlace a cita original Cita con resumen
Li G-F, An X-X, Yu Y, Jiao L-R, Canarutto D, Yu G, Wang G, Wu D-N, Xiao Y. Do proton pump inhibitors influence SARS-CoV- 2 related outcomes? A meta-analysis. Gut 2020:10 de noviembre. [Ref.ID 103790]
11. Cita con resumen
Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ 2020;371:28 de octubre. [Ref.ID 103761]
12.Enlace a cita original Cita con resumen
Gerhard T, Stroup TS, Correll CU, Setoguchi S, Strom BL, Huang C, Tan Z, Crystal S, Olfson M. Mortality risk of antipsychotic augmentation for adult depression. PLoS One 2020;5:30 de septiembre. [Ref.ID 103735]
13.Enlace a cita original Cita con resumen
Lee SW, Ha EK, Yeniova AO, Moon SY, Kim SY, Koh HY, Yang JM, Jeong SJ, Moon SJ, Cho JY, Yoo IK, Yon DK. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut 2021;70:30 de julio. [Ref.ID 103733]
14.Enlace a cita original Cita con resumen
Lund LC, Kristensen KB, Reilev M, Christensen S, Thomsen RW, Christiansen CF, Starving H, Johansen NB, Brun NC, Hallas J, Pottegard A. Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study. PLOS Medicine 2020;17:8 de septiembre. [Ref.ID 103727]
15.Enlace a cita original Cita con resumen
Patorno E, Hernandez-Diaz S, Huybrechts KF, Desai RJ, Cohen JM, Mogun H, Bateman BT. Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: A population-based cohort study nested in the US Medicaid Analytic eXtract dataset. PLOS Medicine 2020;17:1 de septiembre. [Ref.ID 103726]
16.Enlace a cita originalTiene citas relacionadas Cita con resumen
Pau AK, Aberg J, Baker J, Belperio S, Crew P, Gidden DV, Grund B, Gulick RM, Harrison C, Kim A, Lane C, Masur H, Sheikh V, Singh K, Yazdany J, Tebas P, for the National Institutes of Health COVID-19 Treatment Guidelines. Convalescent plasma for the treatment of COVID-19: perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel. Ann Intern Med 2020:25 de septiembre. [Ref.ID 103723]
17. Cita con resumen
Gopalakrishnan C, Bykov K, Fischer MA, Connolly JG, Gagne JJ, Fralick M. Association of fluoroquinolones with the risk of aortic aneurysm or aortic dissection. JAMA Intern Med 2020;180:8 de septiembre. [Ref.ID 103715]
18. Cita con resumen
Dong Y-H, Chang C-H, Wang J-L, Wu L-C, Lin J-W, Toh S. Association of infections and use of fluoroquinolones with the risk of aortic aneurysm or aortic dissection. JAMA Intern Med 2020;180:8 de septiembre. [Ref.ID 103714]
19.Enlace a cita original Cita con resumen
Haugaard JH, Kofoed K, Gislason G, Dreyer L, Egeberg A. Association between drug use and subsequent diagnosis of lupus erythematosus. JAMA Dermatol 2020;156:2 de septiembre. [Ref.ID 103711]
20.Enlace a cita original Cita con resumen
Sun JW, Hernández-Díaz S, Haneuse S, Bourgeois FT, Vine SM, Olfson M, Bateman BT, Huybrechts KF. Association of selective serotonin reuptake inhibitors with the risk of type 2 diabetes in children and adolescents. JAMA Psychiatry 2020:1. [Ref.ID 103710]
Seleccionar todas
 
 1 a 20 de 5184 siguiente >>